Skip to content
ClinCalc Pro
Menu
Vitamin B12 Supplement / Cyanide Antidote Pregnancy: 'Hydroxocobalamin injection should not be used for the treatment of megaloblastic anaemia of pregnancy.' Breast-feeding: 'Hydroxocobalamin is secreted into breast milk but is unlikely to harm the infant.' Fertility: 'No data available'.

Hydroxocobalamin (Vitamin B12)

Brand names: Cobalin-H (IM), Neo-Cytamen (IM), Cyanokit (IV — cyanide antidote)

Used in: Anaemia

Hydroxocobalamin is an injectable form of vitamin B12 used to treat B12 deficiency, including pernicious anaemia and deficiency from malabsorption or dietary causes.

Adult dose

Dose: Vitamin B12 deficiency, by intramuscular injection. Addisonian pernicious anaemia and other macrocytic anaemias WITHOUT neurological involvement: initially 250 micrograms to 1000 micrograms intramuscularly on alternate days for one or two weeks, then 250 micrograms weekly until the blood count is normal; maintenance 1000 micrograms every two or three months. Addisonian pernicious anaemia and other macrocytic anaemias WITH neurological involvement: initially 1000 micrograms on alternate days as long as improvement continues; maintenance 1000 micrograms every two months. Prophylaxis of macrocytic anaemia associated with vitamin B12 deficiency resulting from gastrectomy, ileal resection, certain malabsorption states and vegetarianism: 1000 micrograms every two or three months. SCOPE: this is the intramuscular B12-REPLACEMENT indication only — the cyanide-antidote (Cyanokit) use also named on this page is a different product with its own SPC, is not in this bundle, and no intravenous cyanide regimen is published or implied here.
Route: Intramuscular injection. §4.2, verbatim: 'Method of Administration Intramuscular injection'. The US label in this bundle states of its own product: 'Not for intravenous administration.'
Frequency: Alternate days initially, then weekly until the blood count is normal, then every two or three months for maintenance — every two months for maintenance where there is neurological involvement.
That is exactly this page's primary indication (B12 replacement) by exactly this page's primary route (IM), and Cobalin-H is one of the page's two listed IM brands. || VERBATIM §4.2, every published figure: 'The following dosages are suitable for children and adults.' 'Addisonian pernicious anaemia and other macrocytic anaemias without neurological involvement: Initially: 250 micrograms to 1000 micrograms intramuscularly on alternate days for one or two weeks then 250 micrograms weekly until blood count is normal. Maintenance: 1000 micrograms every two or three months.' 'Addisonian pernicious anaemia and other macrocytic anaemias with neurological involvement: Initially: 1000 micrograms on alternate days as long as improvement continues. Maintenance: 1000 micrograms every two months.' 'Prophylaxis of macrocytic anaemias associated with vitamin B 12 deficiency resulting from gastrectomy, ileal resection, certain ma/absorption states and vegetarianism: 1000 micrograms every two or three months.' (The source prints 'ma/absorption'; read as malabsorption.) || NO MAXIMUM DOSE IS PRINTED anywhere in §4.2 or §4.4, so maxDose is deliberately empty — none has been derived by arithmetic from the regimen. || FOURTH INDICATION IN THE SAME SECTION, not published here because it is not this page's indication: 'Tobacco amblyopia and Leber's optic atrophy: Initially: 1000 micrograms daily by intramuscular injection for two weeks then twice weekly as long as improvement is maintained. Maintenance: 1000 micrograms every three months or as required.' ⚠️ CONFLICT WORTH KNOWING: the US label in this bundle says the opposite — 'Administration to patients with hereditary optic nerve atrophy (Leber's disease) may result in severe and rapid optic nerve atrophy' — and lists it as a contraindication. Check both labels before treating that indication. || BEFORE TREATING, §4.4 verbatim: 'It is advisable to confirm the diagnosis of Vitamin B 12 deficiency before giving hydroxocobalamin; regular monitoring of the blood is recommended. If megaloblastic anaemia fails to respond, folate metabolism should be investigated. Doses in excess of 10 micrograms daily may produce a haematological response in patients with folate deficiency. Indiscriminate administration may mask the true diagnosis.' And: 'Cardiac arrhythmias secondary to hypokalaemia during initial therapy have been reported. Plasma potassium should therefore be monitored during this period.' || PRODUCT STRENGTH: Cobalin-H 1000 microgram/ml, i.e. 1000 micrograms (1 mg) in 1 ml, so a 1000 microgram dose is 1 ml and a 250 microgram dose is 0.25 ml.

Paediatric dose

Dose: As for adults — the SPC gives no separate paediatric figure. §4.2 opens: 'The following dosages are suitable for children and adults.' Without neurological involvement: initially 250 micrograms to 1000 micrograms IM on alternate days for one or two weeks, then 250 micrograms weekly until the blood count is normal, maintenance 1000 micrograms every two or three months. With neurological involvement: initially 1000 micrograms on alternate days as long as improvement continues, maintenance 1000 micrograms every two months.
Route: Intramuscular injection
Frequency: As for adults — see the dose text
Concentration: 1000 micrograms/ml
dosePerKg IS NULL AND MUST STAY NULL: the SPC's paediatric dosing is a fixed microgram regimen, not weight-based, so no weight calculator may run on it and none does (the calculator returns nothing when dosePerKg is null). These are the label's own paediatric figures, stated as suitable for children — nothing has been scaled from the adult dose. concentration 1000 is the source product's strength, Cobalin-H 1000 microgram/ml, so the page renders 'Concentration: 1000 micrograms/ml'. ⚠️ The US label in this bundle warns that its product 'contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with serious and fatal adverse reactions, including "gasping syndrome," in premature infants and neonates' — check the excipients of the actual product in use before giving it to a neonate. Verify any paediatric or neonatal use against a children's formulary and specialist paediatric haematology advice.

Dose adjustments

Renal

Not addressed in the retrieved SPC sections — §4.2 gives no renal-impairment dosing and §4.4 does not mention renal function.

Hepatic

Not addressed in the retrieved SPC sections — §4.2 gives no hepatic-impairment dosing and §4.4 does not mention hepatic function.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • [UK SPC §4.3] 'Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.'
  • [US label cross-check, broader than the UK SPC] Known hypersensitivity to hydroxocobalamin, vitamin B12 preparations, cobalt, benzyl alcohol, or any component of the formulation.
  • [US label cross-check, and DIRECTLY CONTRARY TO THE UK SPC §4.1, which lists Leber's atrophy as an indication] 'Administration to patients with hereditary optic nerve atrophy (Leber's disease) may result in severe and rapid optic nerve atrophy.'

Side effects

  • [§4.8] Metabolism: initial hypokalaemia — potassium falls as B12 treatment drives cellular uptake during haematological recovery
  • [§4.8] Cardiac: arrhythmias secondary to hypokalaemia, reported during initial therapy
  • [§4.8] Blood: reactive thrombocytosis can occur during the first weeks of use in megaloblastic anaemia
  • [§4.8] Immune: hypersensitivity reactions including rash, itching and exanthema; anaphylaxis; antibodies to the hydroxocobalamin-transcobalamin II complex have developed during therapy
  • [§4.8] Injection site reactions including pain, erythema, pruritus, induration and swelling
  • [§4.8] Nervous system: headache, paraesthesia, tremor
  • [§4.8] Gastrointestinal: nausea, vomiting, diarrhoea
  • [§4.8] General: fever, chills, hot flushes, dizziness, malaise, pain
  • [§4.8] Skin: acneiform and bullous eruptions
  • [§4.8] Renal and urinary: chromaturia (discoloured urine)
  • [§4.8] Note: 'There are no modern clinical studies available that can be used to determine the frequency of undesirable effects. Therefore, all the undesirable effects listed are classed as "frequency Not known".'

Interactions

  • [§4.5, carried inside the fetched §4.4 text] Chloramphenicol — 'Parenteral chloramphenicol may attenuate the effect of hydroxocobalamin in anaemia.'
  • [§4.5] Oral contraceptives — 'The serum concentration of hydroxocobalamin may be lowered.'
  • [§4.5] 'The above interactions are unlikely to be of clinical significance but should be taken into account when performing assays for blood concentrations. Vitamin B 12 assays by microbiological techniques are invalidated by antimetabolites and most antibiotics.'

Monitoring

  • Confirm the diagnosis of vitamin B12 deficiency BEFORE giving hydroxocobalamin — indiscriminate administration may mask the true diagnosis (§4.4)
  • Plasma potassium during initial therapy — 'Cardiac arrhythmias secondary to hypokalaemia during initial therapy have been reported. Plasma potassium should therefore be monitored during this period' (§4.4)
  • Regular monitoring of the blood is recommended (§4.4)
  • Blood count response — the without-neurological-involvement regimen is given weekly 'until blood count is normal' (§4.2)
  • Neurological improvement — the with-neurological-involvement regimen continues on alternate days 'as long as improvement continues' (§4.2)
  • If megaloblastic anaemia fails to respond, investigate folate metabolism (§4.4)
  • Assay interpretation: vitamin B12 assays by microbiological techniques are invalidated by antimetabolites and most antibiotics (§4.5)

Clinical monograph

How it works

It is converted to the active coenzymes methylcobalamin and adenosylcobalamin, which are required for DNA synthesis and red cell maturation and for normal neurological function.

Prescribing in practice

  • Establish the diagnosis before treating, as folic acid given alone in B12 deficiency can correct the anaemia while allowing irreversible neurological damage to progress.
  • It is given by intramuscular injection because oral absorption is unreliable in pernicious anaemia and other malabsorptive states.
  • Initiate replacement promptly where neurological involvement is present, with more frequent loading before maintenance.

Monitoring

Check a full blood count and reticulocyte response after starting, and monitor potassium during early treatment of severe megaloblastic anaemia.

Counselling the patient

  • Treatment for pernicious anaemia is usually lifelong and given as regular injections.
  • Report any new tingling, numbness or balance problems.
  • Attend for your scheduled maintenance injections to prevent relapse.

Evidence & guidelines

Hydroxocobalamin is recommended in NICE guidance on B12 deficiency as the standard parenteral replacement for pernicious anaemia and malabsorption.

Reference: BSH Guidelines on Cobalamin and Folate Deficiency 2014; NICE CG126; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.